

Global Fibrosarcoma Drugs and Companies Pipeline Review H2 2016

Fibrosarcoma Treatment Pipeline Review H2 2016

PUNE, INDIA, September 19, 2016
/EINPresswire.com/ -- [Fibrosarcoma](#) - Pipeline Review, H2 2016

Summary

'Fibrosarcoma - Pipeline Review, H2 2016', provides an overview of the Fibrosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects.

Complete report details @

<https://www.wiseguyreports.com/reports/643485-fibrosarcoma-pipeline-review-h2-2016> □



Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/643485-fibrosarcoma-pipeline-review-h2-2016> □

Scope

- The report provides a snapshot of the global therapeutic landscape of Fibrosarcoma
- The report reviews pipeline therapeutics for Fibrosarcoma by companies and universities/research institutes based on information derived from company and industry-

specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Fibrosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Fibrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Fibrosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Fibrosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibrosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/643485-fibrosarcoma-pipeline-review-h2-2016> □

Key Points in Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Fibrosarcoma Overview 7

Therapeutics Development 8

Pipeline Products for Fibrosarcoma - Overview 8

Pipeline Products for Fibrosarcoma - Comparative Analysis 9

Fibrosarcoma - Therapeutics under Development by Companies 10

Fibrosarcoma - Therapeutics under Investigation by Universities/Institutes 11

Fibrosarcoma - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Fibrosarcoma - Products under Development by Companies 15

Fibrosarcoma - Products under Investigation by Universities/Institutes 16

Fibrosarcoma - Companies Involved in Therapeutics Development 17

Advanced Proteome Therapeutics Corporation 17

Advenchen Laboratories, LLC 18

Daiichi Sankyo Company, Limited 19

Elsalys Biotech SAS 20

Millennium Pharmaceuticals Inc 21
Novartis AG 22
Rigontec GmbH 23
Sumitomo Dainippon Pharma Co., Ltd. 24
Fibrosarcoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AL-3818 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
APC-103 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Cellular Immunotherapy for Oncology - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
DSR-6434 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
everolimus - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ImOI-100 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
LK-3 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
MAT-303 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
PLX-7486 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
sapanisertib - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
SEN-461 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
SOM-0777 - Drug Profile 61

Product Description 61
Mechanism Of Action 61
R&D Progress 61
Fibrosarcoma - Dormant Projects 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643485

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.